Drug Profile
Vofatamab - Rainier Therapeutics
Alternative Names: Anti FGR3; B 701; MFGR 1877ALatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator BioClin Therapeutics
- Developer Rainier Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Urogenital cancer
- No development reported Achondroplasia; Multiple myeloma; Solid tumours
Most Recent Events
- 01 Dec 2019 Rainier Therapeutics terminates the phase Ib/II FIERCE-22 trial in Urogenital cancer (Late-stage disease, Monotherapy, Second-line therapy or greater, Metastatic disease, Monotherapy) in the US, Belgium, Denmark, Hungary, France, Germany, Italy, South Korea, Moldova, Netherlands, Poland, Russia, Serbia, Spain, Sweden, Turkey and Ukraine (IV), since the programme was put on hold by the sponsor (NCT03123055)
- 18 Nov 2019 Rainier Therapeutics terminates the phase I/IIb FIERCE-21 trial in Urogenital cancer (Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease, Monotherapy) in the Italy, South Korea, Spain, Sweden, Turkey, Czech Republic, Taiwan, United Kingdom and USA (IV) since the programme was put on hold by the sponsor (NCT02401542)
- 27 Sep 2019 Updated interim efficacy and adverse events data from the FIERCE-22 phase Ib/II trial in Bladder Cancer presented at the 44th European Society for Medical Oncology Congress